Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 196, Issue 12, 2007, Pages 1779-1783

  Edén, Arvid ^a,d   Price, Richard W ^c   Spudich, Serena ^c   Fuchs, Dietmar ^b   Hagberg, Lars ^a   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CENTRAL NERVOUS SYSTEM AGENTS; DIDANOSINE; EFAVIRENZ; IMMUNOGLOBULIN G; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEOPTERIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LEUKOCYTE COUNT; MACROPHAGE ACTIVATION; MICROGLIA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTE COUNT; MIDDLE AGED; NEOPTERIN; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 39149143342     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/523648     Document Type: Article

References (47)

1. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-64.
2. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986; 83:7089-93.
3. Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21:271-6.
4. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158:1079-83.
5. Portegies P, de Gans J, Lange JM, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989; 299:819-21.
6. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81.
7. Hagberg L, Forsman A, Norkrans G, Rybo E, Svennerholm L. Cytological and immunoglobulin findings in cerebrospinal fluid of symptomatic and asymptomatic human immunodeficiency virus (HIV) seropositive patients. Infection 1988; 16:13-8.
8. Fuchs D, Chiodi F, Albert J, et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989; 3:285-8.
9. Sonnerborg AB, von Stedingk LV, Hansson LO, Strannegard OO. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989; 3:277-83.
10. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160:310-6.
11. Elovaara I, Seppala I, Poutiainen E, Suni J, Valle SL. Intrathecal humoral immunologic response in neurologically symptomatic and asymptomatic patients with human immunodeficiency virus infection. Neurology 1988; 38:1451-6.
12. Gisslen M, Chiodi F, Fuchs D, et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 1994; 26:523-33.
13. Marshall DW, Brey RL, Cahill WT, Houk RW, Zajac RA, Boswell RN. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988; 45:954-8.
14. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55:320-8.
15. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002; 16:2145-9.
16. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37:385-90.
17. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993; 33:129-33.
18. Werner ER, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clin Chem 1987; 33:62-6.
19. Hagberg L. Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines 2004; 15:102-6.
20. Gisslen M, Hagberg L. Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med 2001; 2:97-104.
21. Gisolf EH, van Praag RM, Jurriaans S, et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:426-33.
22. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686-96.
23. Yilmaz A. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther 2006; 11:833-7.
24. Havlir DV, Koelsch KK, Strain MC, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191:1164-8.
25. Aurelius E, Forsgren M, Skoldenberg B, Strannegard O. Persistent intrathecal immune activation in patients with herpes simplex encephalitis. J Infect Dis 1993; 168:1248-52.
26. Fredrikson S, Eneroth P, Link H. Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis. Clin Exp Immunol 1987; 67:76-81.
27. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.
28. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42:689-98.
29. Wiley CA, Soontornniyomkij V, Radhakrishnan L, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998; 8:277-84.
30. Tang YW, Huong JT, Lloyd RM Jr, Spearman P, Haas DW. Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma. J Clin Microbiol 2000; 38:4637-9.
31. Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 2005; 79:7959-66.
32. Price RW. The two faces of HIV infection of cerebrospinal fluid. Trends Microbiol 2000; 8:387-91.
33. von Giesen HJ, Adams O, Koller H, Arendt G. Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease. J Neurol 2005; 252:801-7.
34. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 1993; 168:1285-8.
35. Bogner JR, Junge-Hulsing B, Kronawitter U, Sadri I, Matuschke A, Goebel FD. Expansion of neopterin and beta 2-microglobulin in cerebrospinal fluid reaches maximum levels early and late in the course of human immunodeficiency virus infection. Clin Invest 1992; 70:665-9.
36. Elovaara I, Nykyri E, Poutiainen E, Hokkanen L, Raininko R, Suni J. CSF follow-up in HIV-1 infection: intrathecal production of HIV-specific and unspecific IGG, and beta-2-microglobulin increase with duration of HIV-1 infection. Acta Neurol Scand 1993; 87:388-96.
37. Gisslen M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:291-5.
38. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) - a marker of active HIV-related neurodegeneration. J Neurol 2007; 254:1026-32.
39. Resnick L, diMarzo-Veronese F, Schupbach J, et al. Intra-blood-brain- barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med 1985; 313:1498-504.
40. Gisslen M, Lekman A, Fredman P. Cerebrospinal fluid antibodies directed against neuron-associated gangliosides in HIV-1 infection. Infection 2000; 28:143-8.
41. Hagberg L, Norkrans G, Zanetta JP, Lehmann S, Bergstrom T. Cerebrospinal fluid anti-cerebellar soluble lectin antibodies in human immunodeficiency virus type 1 infection. J Neuroimmunol 1992; 36:245-9.
42. Cysique LA, Brew BJ, Halman M, et al. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 2005; 39:426-9.
43. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61:1687-96.
44. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17:1897-906.
45. Mellgren A, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005; 10:701-7.
46. Andersson LM, Hagberg L, Rosengren L, Fuchs D, Blennow K, Gisslen M. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia - case report. BMC Infect Dis 2006; 6:141.
47. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8(Suppl 2):115-21.